Finance

Lists
Why is TNXP down 4,08%?
Dive Deeper
TNXP:NASDAQ
Tonix Pharmaceuticals Holding Corp
2,82 USD
-4,08%
(-0,12) 1D
2,80 USD
-0,71% (-0,020)
After hours
Closed: 18-ноя., 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNXP...
Open
2,90 USD
High
2,98 USD
Low
2,77 USD
Mkt. cap
54,80 млн
Avg. vol.
1,10 млн
Volume
0,00
52-wk high
20,56 USD
52-wk low
2,77 USD
EPS
-12,23 USD
Beta
1,90
Shares outstanding
19,43 млн
No. of employees
142
Open
2,90 USD
High
2,98 USD
Low
2,77 USD
Mkt. cap
54,80 млн
Avg. vol.
1,10 млн
Volume
0,00
52-wk high
20,56 USD
52-wk low
2,77 USD
EPS
-12,23 USD
Beta
1,90
Shares outstanding
19,43 млн
No. of employees
142
News stories
From web sources and news partners
Profile
Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project. Wikipedia
About Tonix Pharmaceuticals Holding Corp
CEOSeth Lederman
Employees142
Founded2007
HeadquartersБеркли Хайтс, Нью Джерси, Америка Кошмо Штаттары
SectorHealth Care
Industry-
Analyst ratings
Based on 4 analysts giving stock ratings to TNXP in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for TNXP in the last 3 months.
Highest
Current 2,82 USD
40,00 USD (+1 318,44%)
Average
23,50 USD (+733,33%)
Lowest
14,00 USD (+396,45%)
Analyst
Recommendation
Action
Price target
Projected
Date
James Molloy
Alliance Global Partners
Buy
Maintained
40,00 USD
+1 318,4%
11/09/2026
Gary Nachman
Canaccord Genuity
Buy
Reiterated
18,00 USD
+538,3%
11/10/2026
Tiago Fauth
Raymond James
Buy
Reiterated
14,00 USD
+396,5%
11/09/2026
Stacy Ku
TD Cowen
Buy
Maintained
22,00 USD
+680,1%
10/21/2026
Robert LeBoyer
Noble Financial
Buy
Reiterated
37,00 USD
+1 212,1%
03/16/2026
Last report
2026-ж., 9-ноя.
Fiscal period
Q3 2026
-2,89 USD / -2,24 USD
-29,02%miss
Revenue / Est. (USD)
17,23 млн / 16,32 млн
+5,62%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
5,39 млн
6,88 млн
13,54 млн
17,23 млн
Cost of goods sold
1,06 млн
1,58 млн
703,00 миң
1,25 млн
Cost of revenue
1,06 млн
1,58 млн
703,00 миң
1,25 млн
Research and development expenses
16,94 млн
18,21 млн
19,42 млн
25,82 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
35,68 млн
28,62 млн
35,96 млн
45,59 млн
Operating expense
52,62 млн
46,84 млн
55,38 млн
71,41 млн
Total operating expenses
53,68 млн
48,42 млн
56,08 млн
72,67 млн
Operating income
-48,29 млн
-41,54 млн
-42,54 млн
-55,43 млн
Other non operating income
32,00 миң
-3,00 миң
551,00 миң
741,00 миң
EBT including unusual items
-46,91 млн
-40,19 млн
-40,55 млн
-53,33 млн
EBT excluding unusual items
-46,91 млн
-40,19 млн
-40,55 млн
-53,33 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-46,91 млн
-40,19 млн
-40,55 млн
-53,33 млн
Net profit margin
-870,32%
-584,38%
-299,41%
-309,44%
Earnings per share
-3,98
-2,93
-2,47
-2,89
Interest and investment income
1,34 млн
1,35 млн
1,43 млн
1,36 млн
Interest expense
-
-
-
-
Net interest expenses
1,34 млн
1,35 млн
1,43 млн
1,36 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-47,80 млн
-40,98 млн
-41,92 млн
-54,79 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору